Aberrant methylation of the TERT promoter in esophageal squamous cell carcinoma

Cancer Genetics

Volumn 208, Issue 12, 2015, Pages 602-609

  Deng, Jiaying ^a,b   Zhou, Daizhan ^c   Zhang, Junhua ^a   Chen, Yun ^a   Wang, Chunyu ^a   Liu, Yun ^b   Zhao, Kuaile ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; Methylation; Telomerase reverse transcriptase; Upstream of the transcription start site (UTSS)

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; TERT GENE; TRANSCRIPTION INITIATION SITE; CHEMISTRY; ESOPHAGUS; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TELOMERASE;

EID: 84949681589     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2015.10.004     Document Type: Article

References (34)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Secretan B., Straif K., Baan R., et al. A review of human carcinogens-part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009, 10:1033-1034.
4. Das P.M., Singal R. DNA methylation and cancer. J Clin Oncol 2004, 22:4632-4642.
5. Zhang X.M., Guo M.Z. The value of epigenetic markers in esophageal cancer. Front Med China 2010, 4:378-384.
6. Egger G., Liang G., Aparicio A., et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
7. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054.
8. Hamilton J.P., Sato F., Greenwald B.D., et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 2006, 4:701-708.
9. Hoque M.O., Begum S., Topaloglu O., et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004, 64:5511-5517.
10. Martin J.A., Forest E., Block J.A., et al. Malignant transformation in human chondrosarcoma cells supported by telomerase activation and tumor suppressor inactivation. Cell Growth Differ 2002, 13:397-407.
11. Poole J.C., Andrews L.G., Tollefsbol T.O. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001, 269:1-12.
12. Horikawa I., Cable P.L., Afshari C., et al. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999, 59:826-830.
13. Liu L., Saldanha S.N., Pate M.S., et al. Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation. Genes Chromosomes Cancer 2004, 41:26-37.
14. Shin K.H., Kang M.K., Dicterow E., et al. Hypermethylation of the hTERT promoter inhibits the expression of telomerase activity in normal oral fibroblasts and senescent normal oral keratinocytes. Br J Cancer 2003, 89:1473-1478.
15. Dessain S.K., Yu H., Reddel R.R., et al. Methylation of the human telomerase gene CpG island. Cancer Res 2000, 60:537-541.
16. Wang Z., Xu J., Geng X., et al. Analysis of DNA methylation status of the promoter of human telomerase reverse transcriptase in gastric carcinogenesis. Arch Med Res 2010, 41:1-6.
17. Kumari A., Srinivasan R., Vasishta R.K., et al. Positive regulation of human telomerase reverse transcriptase gene expression and telomerase activity by DNA methylation in pancreatic cancer. Ann Surg Oncol 2009, 16:1051-1059.
18. Castelo-Branco P., Choufani S., Mack S., et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol 2013, 14:534-542.
19. Iwagami S., Baba Y., Watanabe M., et al. Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. Ann Surg Oncol 2012, 19:2726-2732.
20. Kitkumthorn N., Mutirangura A. Long interspersed nuclear element-1 hypomethylation in cancer: biology and clinical applications. Clin Epigenetics 2011, 2:315-330.
21. Lee H.S., Kim B.H., Cho N.Y., et al. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin Cancer Res 2009, 15:812-820.
22. Baba Y., Huttenhower C., Nosho K., et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 2010, 9:125.
23. Cordaux R., Batzer M.A. The impact of retrotransposons on human genome evolution. Nat Rev Genet 2009, 10:691-703.
24. Guilleret I., Yan P., Grange F., et al. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 2002, 101:335-341.
25. Shigaki H., Baba Y., Watanabe M., et al. LINE-1 hypomethylation in noncancerous esophageal mucosae is associated with smoking history. Ann Surg Oncol 2012, 19:4238-4243.
26. Beleford D., Liu Z., Rattan R., et al. Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Clin Cancer Res 2010, 16:398-409.
27. Peters I., Dubrowinskaja N., Abbas M., et al. DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies. PLoS ONE 2014, 9. e91440.
28. Hu C.Y., Mohtat D., Yu Y., et al. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res 2014, 20:4349-4360.
29. Dai W., Teodoridis J.M., Zeller C., et al. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 2011, 17:4052-4062.
30. Metzger R., Vallbohmer D., Muller-Tidow C., et al. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer. Anticancer Res 2009, 29:1157-1162.
31. Safont M.J., Gil M., Sirera R., et al. The prognostic value of hTERT expression levels in advanced-stage colorectal cancer patients: a comparison between tissue and serum expression. Clin Transl Oncol 2011, 13:396-400.
32. Ogino S., Lochhead P., Chan A.T., et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013, 26:465-484.
33. Barrow T.M., Michels K.B. Epigenetic epidemiology of cancer. Biochem Biophys Res Commun 2014, 455:70-83.
34. Suzuki H., Yamamoto E., Maruyama R., et al. Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun 2014, 455:35-42.